{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vandenbark AA"],"funding":["National Institute of Arthritis and Musculoskeletal and Skin Diseases","National Institute of Allergy and Infectious Diseases","BLRD VA","Office of Research and Development","NIAID NIH HHS","Health Services Research and Development","Biomedical Laboratory Research and Development, VA Office of Research and Development","NIAMS NIH HHS","U.S. Department of Veterans Affairs"],"pagination":["104561"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9714992"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["378"],"pubmed_abstract":["Our previous studies demonstrated increased serum levels of macrophage migration inhibitory factor (MIF-1) and its homologue, MIF-2, in males during MS progression; and that genetically high-MIF-expressing male subjects with relapsing multiple sclerosis (MS) had a significantly greater risk of conversion to progressive MS than lower-MIF-expressing males and females. However, female MS subjects with severe disease expressed higher levels of CD74, the common MIF-1/MIF-2 receptor, on blood cells. In the murine model of MS, experimental autoimmune encephalomyelitis (EAE), both male and female mice lacking MIF-1 and/or MIF-2 were clinically improved during development of moderately severe disease, thus implicating both homologs as co-pathogenic contributors. The current study using MIF-deficient mice with severe acute EAE revealed a highly significant reduction of EAE scores in MIF-1-deficient females, in contrast to only minor and delayed reduction of clinical signs in MIF-1-deficient males. However, clinical EAE scores and factor expression were strongly suppressed in males and further reduced in females after treatment of WT and MIF-1-, MIF-2- and MIF-1/2-DUAL-deficient female and male mice with a MHCII DRα1-MOG-35-55 molecular construct that competitively inhibits MIF-1 & MIF-2 signaling through CD74 as well as T cell activation. These results suggest sex-dependent differences in which the absence of the MIF-1 and/or MIF-2 genotypes may permit stronger compensatory CD74-dependent EAE-inducing responses in males than in females. However, EAE severity in both sexes could still be reduced nearly to background (a \"near cure\") with DRα1-MOG-35-55 blockade of compensatory MIF and CD74-dependent factors known to attract peripheral inflammatory cells into the spinal cord tissue."],"journal":["Cellular immunology"],"pubmed_title":["\"Near Cure\" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct."],"pmcid":["PMC9714992"],"funding_grant_id":["5I01 BX005112","1IK6BX004209","IK6 BX004209","2R42AI122574","1R01AR078334","I01 BX005112","2I01 BX000226","I01 BX000226","R21 AI148409","R41 AI122574","R01 AR078334"],"pubmed_authors":["Offner H","Wiedrick J","Meza-Romero R","Vandenbark AA","Benedek G","Bucala R","Seifert H","Kent G","Gerstner G","Piechycna M"],"additional_accession":[]},"is_claimable":false,"name":"\"Near Cure\" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct.","description":"Our previous studies demonstrated increased serum levels of macrophage migration inhibitory factor (MIF-1) and its homologue, MIF-2, in males during MS progression; and that genetically high-MIF-expressing male subjects with relapsing multiple sclerosis (MS) had a significantly greater risk of conversion to progressive MS than lower-MIF-expressing males and females. However, female MS subjects with severe disease expressed higher levels of CD74, the common MIF-1/MIF-2 receptor, on blood cells. In the murine model of MS, experimental autoimmune encephalomyelitis (EAE), both male and female mice lacking MIF-1 and/or MIF-2 were clinically improved during development of moderately severe disease, thus implicating both homologs as co-pathogenic contributors. The current study using MIF-deficient mice with severe acute EAE revealed a highly significant reduction of EAE scores in MIF-1-deficient females, in contrast to only minor and delayed reduction of clinical signs in MIF-1-deficient males. However, clinical EAE scores and factor expression were strongly suppressed in males and further reduced in females after treatment of WT and MIF-1-, MIF-2- and MIF-1/2-DUAL-deficient female and male mice with a MHCII DRα1-MOG-35-55 molecular construct that competitively inhibits MIF-1 & MIF-2 signaling through CD74 as well as T cell activation. These results suggest sex-dependent differences in which the absence of the MIF-1 and/or MIF-2 genotypes may permit stronger compensatory CD74-dependent EAE-inducing responses in males than in females. However, EAE severity in both sexes could still be reduced nearly to background (a \"near cure\") with DRα1-MOG-35-55 blockade of compensatory MIF and CD74-dependent factors known to attract peripheral inflammatory cells into the spinal cord tissue.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-25T17:08:37.2Z","creation":"2025-04-06T05:03:01.654Z"},"accession":"S-EPMC9714992","cross_references":{"pubmed":["35738135"],"doi":["10.1016/j.cellimm.2022.104561"]}}